Humacyte (NASDAQ:HUMA) Earns “Buy” Rating from BTIG Research

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by stock analysts at BTIG Research in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $2.00 price objective on the stock. BTIG Research‘s price objective would indicate a potential upside of 334.78% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Benchmark cut their target price on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research note on Thursday, August 13th. Williams Trading set a $1.00 price objective on Humacyte in a research report on Friday, October 16th. HC Wainwright reiterated a “buy” rating on shares of Humacyte in a report on Friday, October 16th. Wall Street Zen downgraded Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Friday, October 2nd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Humacyte presently has an average rating of “Moderate Buy” and an average target price of $4.96.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $0.46 on Tuesday. The firm’s 50 day moving average is $0.49 and its two-hundred day moving average is $0.79. Humacyte has a 52 week low of $0.34 and a 52 week high of $1.52. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. The company had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.77 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. As a group, analysts expect that Humacyte will post -0.40 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. HBK Investments L P purchased a new stake in shares of Humacyte in the 2nd quarter valued at about $617,000. Miramontes Capital LLC purchased a new position in shares of Humacyte during the second quarter valued at approximately $85,000. Alyeska Investment Group L.P. bought a new position in Humacyte in the 2nd quarter worth $4,700,000. Beacon Pointe Advisors LLC bought a new position in shares of Humacyte in the 2nd quarter worth approximately $28,000. Finally, Stonepine Capital Management LLC purchased a new stake in Humacyte in the second quarter worth about $180,506. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient.

Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.